Report: How Employers Can Better Manage GLP-1s for Adolescents

Recent data analyzed by Nomi Health reveals a significant rise in both the use and spending on glucagon-like peptide-1 (GLP-1) medications among adolescents between the years 2022 and 2025. This trend has caught the attention of various stakeholders, notably among self-insured employers who provide health benefits to their employees and their dependents.

GLP-1 receptor agonists, originally developed as treatments for type 2 diabetes, have gained wider usage due to their pronounced effects on weight management and metabolic health. The adoption of these therapies by adolescent populations has expanded rapidly in the past few years, contributing to increased expenditure within employer-sponsored health insurance plans.

The financial implications are particularly acute for self-insured employers, who bear the direct costs of medical claims rather than transferring risk to third-party insurers. The abrupt escalation in medication costs from GLP-1 prescriptions prescribed to adolescent beneficiaries has raised concerns about future budgetary pressures.

This development necessitates an assessment of effective management strategies for employers, encompassing policy design, coverage criteria, and utilization management practices. Approaches may include revising formulary management, implementing prior authorization protocols, promoting evidence-based prescribing, and integrating patient education programs.

Additionally, employers must balance cost containment efforts with the clinical needs of adolescents, many of whom rely on these therapies for chronic health conditions or significant weight management challenges. Ensuring access to appropriate care while mitigating potential financial liabilities is a complex endeavor.

The situation underscores the dynamic nature of pharmaceutical innovation and utilization patterns, highlighting the ongoing need for employers and healthcare payers to adapt their strategies in response to evolving clinical practices and public health trends.

As the GLP-1 class of medications continues to see increased adoption among younger patient populations, comprehensive data collection and analysis will be critical to understanding long-term outcomes and cost-effectiveness. Collaborative efforts among employers, healthcare providers, and policymakers are essential to develop sustainable solutions that support adolescent health and fiscal responsibility.

For further details, see the full report at MedCity News: Report: How Employers Can Better Manage GLP-1s for Adolescents.

---

This ongoing trend invites broader discussions around drug pricing, insurance plan design, and healthcare access for younger populations, emphasizing the importance of strategic planning and informed policymaking within the landscape of employer-sponsored health programs.